Profile

Shenzhen Salubris Pharmaceuticals Co., Ltd. (hereinafter referred to as "Salubris") was founded in 1998 and listed on the Shenzhen Stock Exchange in 2009 (Stock code: 002294). It is an innovation-driven pharmaceutical company integrating R&D, production and sales, with a global perspective and a strong presence in China. Salubris adheres to the mission of "Providing exceptional pharmaceutical products for human health", and take high-quality innovative products and evidence-based medical promotion as our core competitiveness. We have established a leading market superiority and a positive brand image in the field of cardiovascular and cerebrovascular diseases.

Salubris has undertaken over seventy major national, provincial and municipal science and technology projects during the "11th Five-Year Plan", "12th Five-Year Plan" and "13th Five-Year Plan" periods . It has won the "China Patent Gold Award" three times and has been honored with the "National Technology Innovation Demonstration Enterprise" , "Best Industrial Enterprise of China's Pharmaceutical R&D Product Line" and other honours.

Innovative Drug R&D Bases